𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C

✍ Scribed by Chun Tao Wai; Chi-Jen Chu; Munira Hussain; Anna S. F. Lok


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
579 KB
Volume
36
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been implicated in spontaneous and interferon alfa (IFN-+related hepatitis B e antigen (HBeAg) seroconversion. We performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype and precore/core promoter mutations on IFN-c~ response in patients with HBeAg-positive chronic hepatitis. Clinical data and stored sera from 109 (95%) patients in the original trial were analyzed. Seventy-three patients received IFN-a and 34 received no treatment (controls). Almost all patients had HBV genotypes B (38%) and C (60%). Antiviral response was achieved in 39% and 17% of IFN-a-treated patients (P = .03) and in 10% and 8% of untreated controls (1" = 38) with HBV genotype B and C, respectively. Multivariate analysis identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV-DNA levels but not IFN-a treatment as independent factors associated with antiviral response. Among the 66 patients with elevated pretreatment ALT level, antiviral response was achieved in 57% and 21% of IFN-a-treated patients (P = .019), and in 25% and 8% of untreated controls (P = .45) with HBV genotype B and C, respectively. Multivariate analysis showed that genotype B and low pretreatment HBV-DNA levels were independent predictors of antiviral response. In conclusion, our data showed that HBV genotype B was associated with a higher rate of IFN-induced HBeAg clearance compared with genotype C. Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B. (HEPATOLOGY 2002;36:1425-1430.) nterferon alfa (IFN-a) and lamivudine are the 2 currently approved treatments for chronic hepatitis B I (CHB) in most countries.' Both agents have limited long-term efficacy. IFN-a is associated with significant adverse effects, whereas long-term therapy with lamivudine may result in drug resistance. Thus, optimal patient selection for treatment is important. High pretreatment


πŸ“œ SIMILAR VOLUMES


Genotypes and titers of hepatitis C viru
✍ Kunihiko Hino; Shigehiko Sainokami; Kazumi Shimoda; Shiro Iino; Yu Wang; Hiroaki πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 708 KB

## Abstract Interferon induces remission in about 50% of patients with chronic hepatitis C, but it is difficult to predict which patients will respond. Host and viral factors were evaluated for correlation with response to interferon in patients with chronic hepatitis C. Recombinant interferon alph

A mutation in the interferon sensitivity
✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 178 KB πŸ‘ 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon

Virological response is associated with
✍ William Sievert; Gregory J. Dore; Geoffrey W. McCaughan; Motoko Yoshihara; Darre πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 336 KB πŸ‘ 1 views

Anemia may increase the likelihood of achieving a sustained virological response (SVR) during pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) infection. To determine whether hemoglobin decline is associated with SVR, we retrospectively evaluated the CHARIOT study of 871 treat

Low vitamin D serum level is related to
✍ Salvatore Petta; Calogero CammΓ ; Concetta Scazzone; Claudio Tripodo; Vito Di Mar πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 543 KB

25-Hydroxyvitamin D (25[OH]D) can potentially interfere with inflammatory response and fibrogenesis. Its role in disease progression in chronic hepatitis C (CHC) and its relation with histological and sustained virological response (SVR) to therapy are unknown. One hundred ninety-seven patients with

Analysis of the complete hepatitis B vir
✍ KaiYu Zhang; Fumio Imazeki; Kenichi Fukai; Makoto Arai; Tatsuo Kanda; Rintaro Mi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 144 KB πŸ‘ 2 views

## Abstract To investigate the relationship between viral factors and the development of chronic hepatitis B, the entire hepatitis B virus (HBV) genome of chronic carriers at different disease stages were analyzed. Eighty genotype C HBV carriers including 12 hepatitis B e antigen (HBeAg) positive a

Relationship of the genomic complexity o
✍ Francesc-Xavier LΓ³pez-Labrador; Sergi AmpurdanΓ¨s; Mireia GimΓ©nez-Barcons; Magdal πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 3 views

In patients with chronic hepatitis C, the influence of the genetic heterogeneity of the hepatitis C virus (HCV) on the progression of liver disease and on the responsiveness to interferon therapy is a matter of controversy. In this study we evaluated the genetic complexity of HCV by singlestrand con